The Receptor for Advanced Glycation End Products Mediates the Chemotaxis of Rabbit Smooth Muscle Cells

Long-term incubation of proteins with glucose leads to advanced glycation end products (AGEs) with fluorescence and a brown color. We recently demonstrated immunologically the intracellular AGE accumulation in smooth muscle cell (SMC)–derived foam cells in advanced atherosclerotic lesions. To understand the mechanism of AGE accumulation in these foam cells, we have now characterized the interaction of AGE proteins with rabbit-cultured arterial SMCs. In experiments at 4°C, 125I-labeled AGE-bovine serum albumin (AGE-BSA) showed a dose-dependent saturable binding to SMCs with an apparent dissociation constant (Kd) of 4.0 μg/ml. In experiments at 37°C, AGE-BSA underwent receptor-mediated endocytosis and subsequent lysosomal degradation. The endocytic uptake of 125I-AGE-BSA was effectively inhibited by unlabeled AGE proteins such as AGE-BSA and AGE-hemoglobin, but not by acetylated LDL and oxidized LDL, well-known ligands for the macrophage scavenger receptor (MSR). Moreover, the binding of 125I-AGE-BSA to SMCs was affected neither by amphoterin, a ligand for one type of the AGE receptor, named RAGE, nor by 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole–hexanoic acid–BSA, a ligand for the other AGE receptors, p60 and p90. This indicates that the endocytic uptake of AGE proteins by SMCs is mediated by an AGE receptor distinct from MSR, RAGE, p60, and p90. To examine the functional role of this AGE receptor, the migratory effects of AGE-BSA on these SMCs were tested. Incubation with 1–50 μg/ml of AGE-BSA for 14 h resulted in significant dose-dependent cell migration. The AGE-BSA–induced SMC migration was chemotactic in nature and was significantly inhibited (∼80%) by an antibody against transforming growth factor-β (TGF-β), and the amount of TGF-β secreted into the culture medium from SMC by AGE-BSA was sevenfold higher than that of control, indicating that TGF-β is involved in the AGE-induced SMC chemotaxis. These data suggest that AGE may play a role in SMC migration in advanced atherosclerotic lesions.

[1]  東隆行 The Receptor for Advanced Glycation End Products Mediates the Chemotaxis of Rabbit Smooth Muscle Cells(メイラード反応後期生成物に対する受容体は血管平滑筋細胞の遊走を担う) , 1997 .

[2]  S. Horiuchi Advanced Glycation End Products (AGE)-Modified Proteins and Their Potential Relevance to Atherosclerosis. , 1996, Trends in cardiovascular medicine.

[3]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[4]  Yong Ming Li,et al.  Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.

[5]  T. Kodama,et al.  Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. , 1995, European journal of biochemistry.

[6]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[7]  T. Kodama,et al.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. , 1995, The American journal of pathology.

[8]  P. Libby,et al.  Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. , 1995, The Journal of clinical investigation.

[9]  T. Sasaki,et al.  Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. , 1994, The Journal of biological chemistry.

[10]  K. Yamada,et al.  Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. , 1994, Clinical nephrology.

[11]  K. Yokote,et al.  Role of phospholipase A2 in expression of the scavenger pathway in cultured aortic smooth muscle cells stimulated with phorbol 12-myristate 13-acetate. , 1994, The Biochemical journal.

[12]  K. Kuwabara,et al.  Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. Sasaki,et al.  Induction of macrophage growth by advanced glycation end products of the Maillard reaction. , 1994, Journal of immunology.

[14]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[15]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[16]  R. Bucala,et al.  Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. , 1993, The American journal of pathology.

[17]  H. Rauvala,et al.  Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. , 1993, The Journal of biological chemistry.

[18]  N. Taniguchi,et al.  beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. , 1993, The Journal of clinical investigation.

[19]  M. Ishiyama,et al.  A New Sulfonated Tetrazolium Salt That Produces a Highly Water-Soluble Formazan Dye , 1993 .

[20]  N. Morisaki,et al.  Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells. , 1993, Biochemical and biophysical research communications.

[21]  S. Kuwajima,et al.  Immunochemical Detection of Advanced Glycation End Products in Renal Cortex From STZ-Induced Diabetic Rat , 1993, Diabetes.

[22]  A. Schmidt,et al.  Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.

[23]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[24]  S. Kuwajima,et al.  Immunochemical Detection of Advanced Glycation End Products in Lens Crystallins From Streptozocin-Induced Diabetic Rat , 1993, Diabetes.

[25]  M. Freeman,et al.  Rabbit aortic smooth muscle cells express inducible macrophage scavenger receptor messenger RNA that is absent from endothelial cells. , 1992, The Journal of clinical investigation.

[26]  T. Kodama,et al.  Coexpression of type I and type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions. , 1992, The American journal of pathology.

[27]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[28]  W. Hurley,et al.  Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.

[29]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[30]  Y. Yazaki,et al.  Platelet-derived growth factor induces c-fms and scavenger receptor genes in vascular smooth muscle cells. , 1992, The Journal of biological chemistry.

[31]  Y. Morino,et al.  Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. , 1992, The Journal of biological chemistry.

[32]  G. Striker,et al.  Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[34]  T. Kadowaki,et al.  Expression of M-CSF receptor encoded by c-fms on smooth muscle cells derived from arteriosclerotic lesion. , 1992, The Journal of biological chemistry.

[35]  Z. Makita,et al.  Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.

[36]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[37]  Yasushi Saito,et al.  Effects of transforming growth factor-β1 on growth of aortic smooth muscle cells Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle , 1991 .

[38]  Y. Morino,et al.  Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. , 1991, The Journal of biological chemistry.

[39]  D. Steinberg,et al.  Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. , 1991, The Journal of clinical investigation.

[40]  N. Morisaki,et al.  Secretion of a potent new migration factor for smooth muscle cells (SMC) by cultured SMC. , 1991, Atherosclerosis.

[41]  R. E. Pitas,et al.  Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters. , 1990, The Journal of biological chemistry.

[42]  N. Morisaki,et al.  Bifunctional effects of transforming growth factor-beta on migration of cultured rat aortic smooth muscle cells. , 1990, Biochemical and biophysical research communications.

[43]  Y. Morino,et al.  Scavenger receptor of human monocytic leukemia cell line (THP-1) and murine macrophages for nonenzymatically glycosylated proteins. , 1989, Biochimica et biophysica acta.

[44]  H. Gerlach,et al.  Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties , 1989, The Journal of experimental medicine.

[45]  R. Majack,et al.  Vascular smooth muscle cells express distinct transforming growth factor-beta receptor phenotypes as a function of cell density in culture. , 1989, The Journal of biological chemistry.

[46]  J. Dasch,et al.  Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. , 1989, Journal of immunology.

[47]  Y. Morino,et al.  Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. , 1988, The Journal of biological chemistry.

[48]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[49]  K. Shirai,et al.  Proliferation and LDL binding of cultured intimal smooth muscle cells from rabbits. , 1988, Atherosclerosis.

[50]  H. Marquardt,et al.  Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. , 1987, Biochemistry.

[51]  A. Cerami,et al.  Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors , 1986, The Journal of experimental medicine.

[52]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[53]  A. Cerami,et al.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Pongor,et al.  Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Wissler,et al.  Ultrastructural and immunohistochemical studies of primary cultures of aortic medial cells. , 1973, Experimental and molecular pathology.

[56]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .